Interface News reporter Yin Jingfei

The controlling shareholder of ST Huawei (600360.SH), Guangji Pharmaceutical (000952. SZ) have been placed on file for investigation.

On October 25, ST Huawei announced that the controlling shareholder Shanghai Pengsheng Technology Industry Co., Ltd. received the "Notice of Case Filing" from the China Securities Regulatory Commission, and because Shanghai Pengsheng was suspected of violating laws and regulations in information disclosure, according to relevant laws and regulations, on October 18, the China Securities Regulatory Commission decided to file a case against it.

ST Huawei was established in 2001, the actual controller is Zeng Tao, the main business is the design and development of power semiconductor devices, chip manufacturing, packaging and testing, sales and other businesses, the company is registered in Jilin City.

The listed company's payment of 1.484 billion yuan is doubtful, and the 2023 financial report is issued a non-standard opinion.

According to the annual report, ST Huawei's 2023 financial report and internal control report were issued with non-standard audit opinions, mainly because the unsettled amount of 504 million yuan in the book balance of its construction projects and the book balance of other non-current assets included 981 million yuan of purchase payments paid in previous years, etc., and the commercial substance of a total of 1.484 billion yuan of payments was doubtful.

The SSE requires ST Huawei to disclose the specific circumstances of the funds involved in the non-standard audit opinion, including the basic information such as the name of the payee, the time of establishment, the registered capital, the main business, and the relationship with the company, as well as the transaction content, payment amount, payment time, internal approval process and specific handler, and clearly state whether the above-mentioned funds flow directly or ultimately to the related party and whether it constitutes the occupation of non-operating funds by the related party.

At the same time, the company is suspected of being held by the actual controller. ST Huawei said in the "Self-inspection Report on Non-standard Audit Opinions in the Annual Report": "After communication between the company and Mr. Zeng Tao, Mr. Zeng Tao claimed that he was not the actual controller of the listed company, and the real actual controller was not yet known, and the shares were still in a state of nominee. ”

As of the first half of 2024, the company's total operating income is 1.079 billion yuan, and the net profit attributable to the parent company is 67.5914 million yuan.

On the same day that the controlling shareholder of ST Huawei was placed on file for investigation, Guangji Pharmaceutical said that the China Securities Regulatory Commission decided to file a case against the company due to suspected violations of information disclosure laws and regulations.

The actual controller of the listed company is the State-owned Assets Supervision and Administration Commission of Hubei Province, registered in Huanggang City, Hubei Province, and is mainly engaged in the research and development, production and sales of vitamin B2 and B6 raw material series products and pharmaceutical preparation products.

It is worth noting that Guangji Pharmaceutical has been warned by the Hubei Securities Regulatory Bureau for violating the letter disclosure regulations.

On April 20, 2023, Guangji Pharmaceutical disclosed the "Announcement on the Correction of Accounting Errors in the Previous Period", adjusting part of the distribution business income of its subsidiary Hubei Guangji Pharmaceutical Jikang Pharmaceutical Co., Ltd. from the gross method to the net method of accounting, and retrospectively adjusting the financial information such as operating income and operating costs in the first quarter of 2021, 2022, 2022 semi-annual report, and third quarter of 2022. The financial information such as operating income and operating costs in the above-mentioned financial reports was inaccurate, which violated the relevant provisions of the Securities Law.

Among them, 51.53 million yuan will be recorded in 2021, and Guangji Pharmaceutical will have an additional revenue of 138 million yuan from January to September 2022

Ruan Shu, as the chairman and general manager of Guangji Pharmaceutical, Hu Mingfeng, as the chief financial officer of Guangji Pharmaceutical, and Zheng Bin, as the secretary of the board of directors of Guangji Pharmaceutical, are primarily responsible for the above-mentioned violations of Guangji Pharmaceutical. The Hubei Securities Regulatory Bureau decided to take administrative supervision measures of issuing warning letters to the above three people, and recorded them in the integrity file of the securities and futures market in accordance with the regulations.

In terms of performance, Guangji Pharmaceutical has continued to lose money for nearly a year and a half, with net losses in 2023 and the first half of 2024. From January to June 2024, the total operating income was 296 million yuan, down 13.80% from the same period last year, and the net profit was 107 million yuan, down 313.28% from the same period last year.

It should be noted that this week, including Guangji Pharmaceutical, five pharmaceutical companies have been filed by the CSRC on suspicion of illegal information disclosure and insider trading.

On October 23, Nanwei Co., Ltd. (603880. SH) announced that the company's controlling shareholder and actual controller Li Ping received a notice of filing issued by the CSRC on October 23, and Xiang Qinhua, the company's chief financial officer, received a notice of filing issued by the CSRC on the same day.

On October 23, Nuotai Biotech (688076. SH) announced in the evening that due to suspected violations of information disclosure laws and regulations, the company and one of the actual controllers, Zhao Dezhong, recently received a notice from the CSRC to file a case, and the CSRC decided to file the case. After self-examination, the case may involve matters related to the company's technology transfer in 2021.

On October 22, Humanwell Pharma (600079. SH) announced in the evening that due to suspected violations of information disclosure laws and regulations, the company and its controlling shareholder Wuhan Modern Technology Industry Group Co., Ltd. received the "Notice of Case Filing" from the China Securities Regulatory Commission on October 22, and the China Securities Regulatory Commission decided to file a case against the company and its controlling shareholder Modern Technology.

On October 21, Sihuan Biotech (000518. SH) announced in the evening that due to suspected violations of information disclosure laws and regulations, the China Securities Regulatory Commission issued a "Notice of Case Filing" to Lu Keping, the actual controller of the company, and recently decided to file a case against him.

A secretary of the board of directors of a listed company told Jiemian News: "Failure to timely disclose the occupation of non-operating funds and related party transactions of related parties, failure to timely disclose periodic reports, and failure to timely disclose temporary announcementsIn recent years, the regulatory authorities have increased the investigation and punishment of information disclosure violations. There is zero tolerance for information disclosure violations, which is conducive to the healthy development of the capital market ecology. ”